It inhibited the tumor growth by decreasing proliferating cell nuclear antigen (PCNA) and abrogated the de novo lipogenesis of cancer cells by the initiation of AMP-activated protein kinase (AMPK) signaling and reduction of the lipogenesis enzymes levels (acetyl-CoA carboxylase, fatty acid synthase) [122]. The gene discussed is FASN; the disease is cancer.